Clinical trial · Interventional
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
A Phase 2, Multi-Center, Randomized, Open-Label Study of Two Dose Levels of IMOxine® (IMO-2055 for Injection) in Patients With Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
NCT00729053CI-TRIAL-00033288completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Multi-Center * Randomized * Open-Label Study of single agent IMO-2055 * Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IMO-2055 | Drug | Immunomodulatory Oligonucleotide | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Previous treatment, 0.16mg/kg
- description
- Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
- interventionNames
- Drug: IMO-2055
- type
- ACTIVE_COMPARATOR
- label
- Previous treatment, 0.64mg/kg
- description
- Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
- interventionNames
- Drug: IMO-2055
- type
- ACTIVE_COMPARATOR
- label
- Treatment Naive, 0.16mg/kg
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed stage IV clear cell renal carcinoma with metastatic or locally recurrent disease that is not surgically resectable. * At least one measurable lesion * Adequate organ function * Any prior treatment of renal cell cancer was concluded at least 4 weeks prior. * If female and of childbearing potential, a negative serum pregnancy test performed and documented no more than 14 days before the first dose of study drug. Exclusion Criteria: * Known untreated central nervous system (CNS) metastasis * Pre-existing autoimmune or antibody-mediated diseases * Other significant medical disease.
References
Publications (0)
Data not yet available
No reference posted for this study.